Wnt signalling in pituitary development and tumorigenesis

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages

  Chambers, T J G ^a   Giles, A ^a   Brabant, G ^b   Davis, J R E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Adenoma; Development; Pituitary; Tumorigenesis; Wnt

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE C; T CELL FACTOR 4; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR HESX1; TRANSCRIPTION FACTOR PITX1; TRANSCRIPTION FACTOR PITX2; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; WNT1 PROTEIN; WNT4 PROTEIN; WNT5A PROTEIN; WNT6 PROTEIN;

ACTH SECRETING CELL; ALOPECIA NEUROLOGICAL DEFECTS AND ENDOCRINOPATHY SYNDROME; CARCINOGENESIS; CARNEY COMPLEX; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CRANIOPHARYNGIOMA; DOWN REGULATION; ENDOCRINE DISEASE; GONADOTROPIN SECRETING CELL; GROWTH HORMONE SECRETING CELL; HUMAN; HYPOPHYSIS; HYPOPHYSIS ADENOMA; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROBLASTOMA; NONHUMAN; PROLACTIN SECRETING CELL; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SKIN BIOPSY; TSH SECRETING CELL; UPREGULATION; WNT SIGNALING PATHWAY;

ADENOMA; DEVELOPMENT; PITUITARY; TUMORIGENESIS; WNT;

ANIMALS; CRANIOPHARYNGIOMA; HUMANS; ORGANOGENESIS; PITUITARY GLAND; PITUITARY NEOPLASMS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84879476826     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0005     Document Type: Review

References (50)

1. Acunzo J, Roche C, Defilles C, Thirion S, Quentien M.-H., Figarella-Branger D, Graillon T, Dufour H, Brue T, Pellegrini I et al. 2011 Inactivation of pitx2 transcription factor induced apoptosis of gonadotroph tumoral cells. Endocrinology 152 3884-3892. (doi:10.1210/en.2011-1216)
2. Alatzoglou KS, Andoniadou CL, Kelberman D, Buchanan CR, Crolla J, Arriazu MC, Roubicek M, Moncet D, Martinez-Barbera JP & Dattani MT 2011 Sox2 haploinsufficiency is associated with slow progressing hypothalamo-pituitary tumours. Human Mutation 32 1376-1380. (doi:10.1002/humu.21606)
3. Almeida MQ, Muchow M, Boikos S, Bauer AJ, Griffin KJ, Tsang KM, Cheadle C, Watkins T, Wen F, Starost MF et al. 2010 Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53C/K or Rb1C/K backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and wnt signaling. Human Molecular Genetics 19 1387-1398. (doi:10.1093/hmg/ddq014)
4. Andoniadou CL, Signore M, Young RM, Gaston-Massuet C, Wilson SW, Fuchs E & Martinez-Barbera JP 2011 HESX1- and TCF3-mediated repression of Wnt/β-catenin targets is required for normal development of the anterior forebrain. Development 138 4931-4942. (doi:10.1242/dev.066597)
5. Andoniadou CL, Gaston-Massuet C, Reddy R, Schneider RP, Blasco MA, Tissier PL, Jacques TS, Pevny LH, Dattani MT & Martinez-Barbera JP 2012 Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathologica 124 259-271. (doi:10.1007/s00401-012-0957-9)
6. Archbold HC, Yang YX, Chen L & Cadigan KM 2012 How do they do wnt they do?: regulation of transcription by the wnt/β-catenin pathway Acta Physiologica 204 74-109. (doi:10.1111/j.1748-1716.2011.02293.x)
7. Brinkmeier ML, Potok MA, Cha KB, Gridley T, Stifani S, Meeldijk J, Clevers H & Camper SA 2003 TCF and Groucho-related genes influence pituitary growth and development. Molecular Endocrinology 17 2152-2161. (doi:10.1210/me.2003-0225)
8. Brinkmeier ML, Potok MA, Davis SW & Camper SA 2007 TCF4 deficiency expands ventral diencephalon signaling and increases induction of pituitary progenitors. Developmental Biology 311 396-407. (doi:10.1016/j.ydbio.2007.08. 046)
9. Campanini ML, Colli LM, Paixao BMC, Cabral TPF, Amaral FC, Machado HR, Neder LS, Saggioro F, Moreira AC, Antonini SRR et al. 2010 CTNNB1 gene mutations, pituitary transcription factors, and microRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas. Hormones & Cancer 1 187-196. (doi:10.1007/s12672-010-0041-7)
10. Cani CMG, Matushita H, Carvalho LRS, Soares IC, Brito LP, Almeida MQ & Mendonça BB 2011 PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations. Clinics 66 1849-1854.
11. Cha KB, Douglas KR, Potok MA, Liang H, Jones SN & Camper SA 2004 Wnt5a signaling affects pituitary gland shape. Mechanisms of Development 121 183-194. (doi:10.1016/j.mod.2003.12.002)
12. Clevers H & Nusse R 2012 Wnt/β-catenin signaling and disease. Cell 149 1192-1205. (doi:10.1016/j.cell.2012.05.012)
13. Dasen JS, Barbera JP, Herman TS, Connell SO, Olson L, Ju B, Tollkuhn J, Baek SH, Rose DW & Rosenfeld MG 2001 Temporal regulation of a paired-like homeodomain repressor/TLE corepressor complex and a related activator is required for pituitary organogenesis. Genes and Development 15 3193-3207. (doi:10.1101/gad.932601)
14. Elston MS, Gill AJ, Conaglen JV, Clarkson A, Shaw JM, Law AJJ, Cook RJ, Little NS, Clifton-Bligh RJ, Robinson BG et al. 2008 Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 149 1235-1242. (doi:10.1210/en.2007-0542)
15. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML & McCutcheon IE 2004 The prevalence of pituitary adenomas: a systematic review. Cancer 101 613-619. (doi:10.1002/cncr.20412)
16. Formosa R, Gruppetta M, Falzon S, Santillo G, DeGaetano J, Xuereb-Anastasi A & Vassallo J 2012 Expression and clinical significance of Wnt players and survivin in pituitary tumours. Endocrine Pathology 23 123-131. (doi:10.1007/s12022-012-9197-8)
17. Gage PJ, Suh H & Camper SA 1999 Dosage requirement of Pitx2 for development of multiple organs. Development 126 4643-4651.
18. Gardner S, Maudsley S, Millar RP & Pawson AJ 2007 Nuclear stabilization of β-catenin and inactivation of glycogen synthase kinase-3b by gonadotropin-releasing hormone: targeting wnt signaling in the pituitary gonadotrope. Molecular Endocrinology 21 3028-3038. (doi:10.1210/me.2007-0268)
19. Gaston-Massuet C, Andoniadou CL, Signore M, Jayakody SA, Charolidi N, Kyeyune R, Vernay B, Jacques TS, Taketo MM, Le Tissier P et al. 2011 Increased wingless (wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans. PNAS 108 11482-11487. (doi:10.1073/pnas. 1101553108)
20. Giles A, Madec F, Friedrichsen S, Featherstone K, Chambers T, Harper CV, Resch J, Brabant G & Davis JRE 2011 Wnt signaling in estrogen-induced lactotroph proliferation. Journal of Cell Science 124 540-547. (doi:10.1242/jcs.078642)
21. Glover CE, Gurley KE, Kim K-H, Storer B, Fero ML & Kemp CJ 2009 Endocrine dysfunction in p27kip1 deficient mice and susceptibility to wnt-1 driven breast cancer. Carcinogenesis 30 1058-1063. (doi:10.1093/carcin/bgp089)
22. Hassanein AM, Glanz SM, Kessler HP, Eskin TA & Liu C 2003 β-catenin is expressed aberrantly in tumors expressing shadow cells. pilomatricoma, craniopharyngioma, and calcifying odontogenic cyst. American Journal of Clinical Pathology 120 732-736. (doi:10.1309/EALEG7LD6W7167PX)
23. Kelberman D, de Castro SCP, Huang S, Crolla JA, Palmer R, Gregory JW, Taylor D, Cavallo L, Faienza MF, Fischetto R et al. 2008 Sox2 plays a critical role in the pituitary, forebrain, and eye during human embryonic development. Journal of Clinical Endocrinology and Metabolism 93 1865-1873. (doi:10.1210/jc.2007-2337)
24. Kerr JM, Gordon DF, Woodmansee WW, Sarapura VD, Ridgway EC & Wood WM 2005 Growth arrest of thyrotropic tumors by thyroid hormone is correlated with novel changes in wnt-10a. Molecular and Cellular Endocrinology 238 57-67. (doi:10.1016/j.mce.2005.03.004)
25. Kestler HA & Kühl M 2008 Fromindividual wnt pathways towards a wnt signallingnetwork. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 363 1333-1347. (doi:10.1098/rstb.2007. 2251)
26. Khattak MNK, Buchfelder M, Kleindienst A, Schöfl C & Kremenevskaja N 2010 Crh and srif have opposite effects on the wnt/β-catenin signalling pathway through pka/gsk-3β in corticotroph pituitary cells. Cancer Investigation 28 797-805. (doi:10.3109/07357907.2010. 494318)
27. Kioussi C, Briata P, Baek SH, Rose DW, Hamblet NS, Herman T, Ohgi KA, Lin C, Gleiberman A, Wang J et al. 2002 Identification of a wnt/dvl/β-catenin/ pitx2 pathway mediating cell-type-specific proliferation during development. Cell 111 673-685. (doi:10.1016/S0092-8674(02)01084-X)
28. Kremenevskaja N, von Wasielewski R, Rao AS, Schöfl C, Andersson T & Brabant G 2005 Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24 2144-2154. (doi:10.1038/sj.onc.1208370)
29. Levy A & Lightman S 2003 Molecular defects in the pathogenesis of pituitary tumours. Frontiers in Neuroendocrinology 24 94-127. (doi:10.1016/S0091-3022(03)00012-8)
30. Li S, Crenshaw EB, Rawson EJ, Simmons DM, Swanson LW & Rosenfeld MG 1990 Dwarf locus mutants lacking three pituitary cell types result from mutations in the pou-domain gene pit-1. Nature 347 528-533. (doi:10.1038/ 347528a0)
31. Miyakoshi T, Takei M, Kajiya H, Egashira N, Takekoshi S, Teramoto A & Osamura RY 2008 Expression of wnt4 in human pituitary adenomas regulates activation of the β-catenin-independent pathway. Endocrine Pathology 19 261-273. (doi:10.1007/s12022-008-9048-9)
32. Miyakoshi T, Kajiya H, Miyajima K, Takei M, Tobita M, Takekoshi S & Osamura RY 2009 The expression of wnt4 is regulated by estrogen via an estrogen receptor α-dependent pathway in rat pituitary growth hormone-producing cells. Acta Histochemica et Cytochemica 42 205-213. (doi:10.1267/ahc.09033)
33. Moreno CS, Evans C-O, Zhan X, Okor M, Desiderio DM & Oyesiku NM 2005 Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Research 65 10214-10222. (doi:10.1158/0008-5472.CAN-05-0884)
34. Mould AW, Duncan R, Serewko-Auret M, Loffler KA, Biondi C, Gartside M, Kay GF & Hayward NK 2009 Global expression profiling of sex cord stromal tumors from men1 heterozygous mice identifies altered TGF-β signaling, decreased gata6 and increased csf1r expression. International Journal of Cancer 124 1122-1132. (doi:10.1002/ijc.24057)
35. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY & Nakayama K 1996 Mice lacking p27(kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 707-720. (doi:10.1016/S0092-8674(00)81237-4)
36. Nousbeck J, Spiegel R, Ishida-Yamamoto A, Indelman M, Shani-Adir A, Adir N, Lipkin E, Bercovici S, Geiger D, van Steensel MA et al. 2008 Alopecia, neurological defects, and endocrinopathy syndrome caused by decreased expression of rbm28, a nucleolar protein associated with ribosome biogenesis. American Journal of Human Genetics 82 1114-1121. (doi:10.1016/j.ajhg.2008.03.014)
37. Nusse R 2012 Wnt signaling. Cold Spring Harbor Perspectives in Biology 4 a011163. (doi:10.1101/cshperspect.a011163)
38. Olson LE, Tollkuhn J, Scafoglio C, Krones A, Zhang J, Ohgi KA, Wu W, Taketo MM, Kemler R, Grosschedl R et al. 2006 Homeodomainmediated β-catenin-dependent switching events dictate cell-lineage determination. Cell 125 593-605. (doi:10.1016/j.cell.2006.02.046)
39. Pope C, McNeilly JR, Coutts S, Millar M, Anderson RA & McNeilly AS 2006 Gonadotrope and thyrotrope development in the human and mouse anterior pituitary gland. Developmental Biology 297 172-181. (doi:10.1016/j.ydbio.2006. 05.005)
40. Potok MA, Cha KB, Hunt A, Brinkmeier ML, Leitges M, Kispert A & Camper SA 2008 Wnt signaling affects gene expression in the ventral diencephalon and pituitary gland growth. Developmental Dynamics 237 1006-1020. (doi:10.1002/dvdy.21511)
41. Salisbury TB, Binder AK, Grammer JC & Nilson JH 2007 Maximal activity of the luteinizing hormone β-subunit gene requires β-catenin. Molecular Endocrinology 21 963-971. (doi:10.1210/me.2006-0383)
42. Schittenhelm J, Psaras T, Honegger J, Trautmann K, Meyermann R & Beschorner R 2009 No evidence for wt1 involvement in a β-cateninindependent activation of the wnt signaling pathway in pituitary adenomas. Endocrine Pathology 20 158-162. (doi:10.1007/s12022-009-9078-y)
43. Sekine S, Shibata T, Kokubu A, Morishita Y, Noguchi M, Nakanishi Y, Sakamoto M & Hirohashi S 2002 Craniopharyngiomas of adamantinomatous type harbor β-catenin gene mutations. American Journal of Pathology 161 1997-2001. (doi:10.1016/S0002-9440(10)64477-X)
44. Semba S, Han SY, Ikeda H & Horii A 2001 Frequent nuclear accumulation of β-catenin in pituitary adenoma. Cancer 91 42-48. (doi:10.1002/1097- 0142(20010101)91:1!42::AID-CNCR6O3.0.CO;2-7)
45. Spiegel R, Shalev SA, Adawi A, Sprecher E & Tenenbaum-Rakover Y 2010 ANE syndrome caused by mutated RBM28 gene: a novel etiology of combined pituitary hormone deficiency. European Journal of Endocrinology 162 1021-1025. (doi:10.1530/EJE-10-0077)
46. Suh H, Gage PJ, Drouin J & Camper SA 2002 Pitx2 is required at multiple stages of pituitary organogenesis: pituitary primordium formation and cell specification. Development 129 329-337.
47. Treier M, Gleiberman AS, O'Connell SM, Szeto DP, McMahon JA, McMahon AP & Rosenfeld MG 1998 Multistep signaling requirements for pituitary organogenesis In vivo. Genes and Development 12 1691-1704. (doi:10.1101/gad.12. 11.1691)
48. Varea O, Garrido JJ, Dopazo A, Mendez P, Garcia-Segura LM & Wandosell F 2009 Estradiol activates β-catenin dependent transcription in neurons. PLoS ONE 4 e5153. (doi:10.1371/journal.pone.0005153)
49. Wu C-I, Hoffman JA, Shy BR, Ford EM, Fuchs E, Nguyen H & Merrill BJ 2012 Function of wnt/β-catenin in counteracting tcf3 repression through the tcf3-β-catenin interaction. Development 139 2118-2129. (doi:10.1242/dev.076067)
50. Yi F, Pereira L, Hoffman JA, Shy BR, Yuen CM, Liu DR & Merrill BJ 2011 Opposing effects of tcf3 and tcf1 control wnt stimulation of embryonic stem cell self-renewal. Nature Cell Biology 13 762-770. (doi:10.1038/ncb2283)